Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03020563

Enrollment

Registered

2017-01-13

Start date

2017-08-23

Completion date

2018-01-01

Last updated

2018-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clavicle Fracture

Brief summary

To determine whether liposomal bupivacaine wound infiltration decreases pain scores and narcotic use when compared to bupivacaine alone after open reduction internal fixation of midshaft clavicle fractures.

Interventions

DRUGLiposomal Bupivacaine

Liposomal Bupivacaine

DRUGBupivacaine

Bupivacaine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Mid-shaft Clavicle Fracture treated with ORIF

Exclusion criteria

* Unable to be contacted for 72 hours post surgery * Other concurrent surgical procedures * Chronic narcotic user

Design outcomes

Primary

Measure	Time frame	Description
Visual Analogue Pain Scale Averages between the two treatments	72 hours post surgery	Scale is based on 1-10 with 1 being the lowest pain and 10 being the highest pain.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026